10-K/A: Autonomix Medical Files 10-K/A for Fiscal 2026

Autonomix Medical, Inc. filed an amendment to its 2026 Annual Report to include required Part III disclosures regarding governance and executive compensation.

Summary

• This filing is an amendment (Form 10-K/A) to the previously filed Annual Report for the fiscal year ended March 31, 2026.
• The primary purpose is to provide information required by Items 10 through 14 of Part III, which were originally omitted in reliance on incorporation by reference from a proxy statement.
• The document provides updated biographical information for directors and executive officers as of June 1, 2026.
• It details executive compensation for fiscal years 2025 and 2026, including salary, bonuses, and equity award cancellations.
• The filing includes updated Sarbanes-Oxley Section 302 certifications from the CEO and CFO.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing; it provides necessary transparency regarding governance and compensation but does not signal a change in the company's fundamental operational trajectory.

Positives

• The company maintains a formal Dodd-Frank Restatement Recoupment Policy to ensure accountability.
• The board includes independent directors with significant experience in the medical device and pharmaceutical industries.
• The company has established clear board committees (Audit, Compensation, Nominating and Governance) with written charters.

Negatives

• The company has a history of cancelling stock options for key executives, which may indicate past misalignment or volatility in equity incentive programs.
• Several key executives, including the Chief Medical Officer and Chief Technology Officer, serve on a part-time basis (25% of working time).
• The company has experienced significant turnover in executive leadership roles over the past two years.

Risks

• Reliance on part-time executive leadership for critical roles like Chief Medical Officer and Chief Technology Officer.
• Potential for future dilution and volatility associated with various outstanding warrants and equity compensation plans.
• The company is in a developmental stage and remains subject to the risks inherent in medical device commercialization and regulatory approval processes.

Future Outlook

The company intends to continue its focus on clinical proof of concept trials and securing strategic partnerships, with executive bonuses for fiscal 2027 tied to these specific corporate goals.

Management Comments

• Management confirms that the report does not contain any untrue statement of a material fact or omit to state a material fact.

Industry Context

StockSavvy.ai notes that Autonomix Medical operates in the highly competitive medical device sector, where reliance on part-time executive leadership and frequent equity restructuring are often indicators of a company managing tight cash flows while attempting to reach clinical milestones.

Comparison to Industry Standards

• The company's governance structure, including the use of independent committees, aligns with standard practices for Nasdaq-listed small-cap medical device firms.
• The use of part-time C-suite executives is unconventional for larger, established medical device companies but is occasionally observed in early-stage, venture-backed entities.

Corporate Governance

Stakeholder Impact

• Shareholders receive updated transparency regarding executive compensation and board composition.
• The disclosure of equity cancellations and part-time executive roles provides clarity on management alignment.

Next Steps

• Annual Shareholder Meeting
• Continued clinical proof of concept trials
• Ongoing pursuit of strategic partnerships

Key Dates

Keywords

Autonomix Medical, AMIX, Medical Devices, SEC Filing, 10-K/A, Executive Compensation, Corporate Governance